Amyloid Oligomers: The Missing Piece in AD Puzzle
Beta amyloid proteins are produced and cleared from the brain as a part of a normal biological process. With advanced age, the clearance of beta amyloid is impaired, and beta amyloid proteins aggregate into small soluble amyloid aggregates, called oligomers, as well as longer amyloid fibrils and plaques, the hallmark pathology of Alzheimer’s disease (AD). Oligomers have been identified as the toxic agents that lead to injury of brain cells and neurodegeneration, progressive cognitive and behavioral impairment, and ultimately, death.
Aging is the main risk factor for the development of AD, resulting in the growing prevalence of the disease as people live longer. Alzheon is building a pipeline of oral, beta amyloid-targeting drugs to block this pathological process and to treat a wide range of diseases caused or worsened by beta amyloid deposits.